EVERSANA a leading independent provider of global commercial services to the life sciences industry, appointed Ed Cox to executive VP, strategic alliances and global head of the company’s new digital medicine practice area.
Management says Cox is widely recognized as a preeminent thought leader in digital therapeutics. He joins EVERSANA from Dthera Sciences, where, as its CEO, Cox earned the FDA’s Breakthrough Device designation for a digital therapeutic to treat the behavioral symptoms of Alzheimer’s disease.
According to company leaders, Cox’s addition further accelerates EVERSANA’s leading digital medicine and digital therapeutic capabilities across the pharmaceutical industry, which includes the company’s recent partnerships to commercialize digital medicines with companies and improve patients’ lives with behavioral technology platforms.
“Digital medicine rapidly evolves the way we diagnose, treat, and manage conditions, and we must be prepared to help our clients understand this new paradigm and how they can most effectively commercialize these vital therapies,” says CEO Jim Lang. “We’re proud to welcome a thought leader like Ed to our team. He understands our clients’ complex needs and how to create the right pathways to commercial success.”
“I’m thrilled to join EVERSANA because we have the opportunity to directly impact the two critical questions facing the fields of digital medicine and digital therapeutics: how can companies directly commercialize these products, and how can pharmaceutical companies effectively deploy digital therapies into their product portfolios to maximize the value and impact,” Cox says. “EVERSANA’s commercial platform, their commitment to innovation through meaningful partnerships, and their expanding global footprint, especially in Europe and Asia, present so many opportunities for the future of digital medicine.”